ASCO26: Cancer vaccines and at-home injectable drugs continue to show promise

A number of companies presented new data on their cancer vaccine candidates at ASCO 2026. A number of companies presented new data on their cancer vaccine candidates at ASCO 2026. J&J’s Rybrevant and cancer vaccines are showing benefit, with detailed data presented at ASCO. Credit: Hindi Studio / Shutterstock.com During the American Society of Clinical Oncology (ASCO) meeting 2026, data were presented for a number of cancer vaccines, including in melanoma, glioblastoma and head and neck squamous cell carcinoma. Cancer vaccines are working their way through clinical trials; however, there may be some difficulties due to growing scepticism around their…

Source: Pharmaceutical Technology